VA-HEMOSONICS
HemoSonics is excited to announce that its new QStat Cartridge, an extension of its groundbreaking Quantra Hemostasis System, has registered for CE Mark and is now commercially available in Europe and Hong Kong. The utility of the Quantra System, which was previously available with the QPlus Cartridge for cardiovascular and major orthopedic surgeries, is now expanded with the addition of the QStat Cartridge and can now be used across the hospital in trauma surgery and liver transplant settings. The Quantra System provides rapid, actionable coagulation results at the point of care, giving clinicians the opportunity to make informed bleeding management decisions when time is critical.
Improving patient outcomes and facilitating goal-directed therapy is the primary focus of any diagnostic system. But the new Quantra System is breaking new ground in point-of-care viscoelastic testing (VET) efficiency by combining rapid time to results, clear outputs, and a simple intuitive design. SEER (Sonic Estimation of Elasticity via Resonance) Sonorheometry, the revolutionary ultrasound technology, is the foundation of this remarkably efficient and reliable analyzer, which now offers an expanded menu of whole-blood tests in two self-contained cartridges; QPlus® for cardiac and major orthopedic surgery, and QStat for trauma and liver transplant surgery.
The QStat Cartridge is a fully sealed, room-temperature stable, disposable cartridge that offers a panel of viscoelastic coagulation tests, including Clot Time (CT), Clot Stiffness (CS), Fibrinogen Contribution to Clot Stiffness (FCS), Platelet Contribution to Clot Stiffness (PCS), and Clot Stability to Lysis (CSL). All tests except the latter take 25 minutes or less to produce valid results (typically 12-15 minutes), whereas the clot lysis test (CSL) is enabled to run for up to 60 minutes. The Quantra System requires less than 60 seconds of operator’s hands-on time – and requires no pipetting or wait time after draw. Results are provided on an easy-to-read, user-friendly “dials” interface that does not require extensive training.
Studies have demonstrated strong correlation between the Quantra System and both standard laboratory tests and other viscoelastic hemostasis assays. In addition, the QStat Cartridge provides novel parameters designed specifically to give clear actionable information in critical care settings. The Quantra System reports both fibrinogen (FCS) and platelet contributions (PCS) to clot stiffness, giving clinicians the opportunity to quickly consider the most appropriate therapies to apply when bleeding is a concern. The Clot Stability to Lysis (CSL) test provides an adaptive and confirmatory result based on the level and onset time of clot lysis. Additionally, the Quantra QStat System directly analyzes and compares changes in clot stiffness in both the presence and absence of tranexamic acid, thus automatically correcting for potentially confounding results inherent to earlier VET systems.
“Trauma and liver surgeries pose an enormous risk of acute bleeding,” said Timothy J. Fischer , President and Chief Executive Officer of HemoSonics. “The Quantra QStat System is a breakthrough in point-of-care bleeding management because it provides rapid, reliable, and novel information to aid clinicians in their decision making in the ER, trauma bay, or post-operative ICU. What makes the new QStat Cartridge unique is its unparalleled ease of use and its innovative coagulation tests for critical injury and liver transplant, including Platelet Contribution to Clot Stiffness and Clot Stability to Lysis.”
Availability
The Quantra Hemostasis System, including QPlus and QStat Cartridges and 2 levels of external quality controls, is commercially available in countries within Europe.
In the United States, the Quantra Hemostasis Analyzer, QPlus Cartridge and associated external quality controls comprise the Quantra® QPlus® System which received de novo marketing authorization by the FDA in March of 2019. In the United States the QStat Cartridge is available for investigational use only.
About HemoSonics
HemoSonics is a medical device company with the primary mission to deliver clinical tools that provide actionable information in the critical care settings; resulting in better care for patients and lower overall medical costs.
The Quantra Hemostasis Analyzer, the flagship product of HemoSonics, is designed to improve patient outcomes and reduce healthcare costs by providing unique and optimized coagulation information, for easy and fast interpretation and simple, more efficient point-of-care bleeding management workflows.
HemoSonics is headquartered in Charlottesville, VA, with research, development and manufacturing facilities in Durham, NC. For more information, visit www.hemosonics.com .
HemoSonics is part of the Stago group, a leading company in the in vitro Diagnostics industry dedicated to the exploration of thrombosis and hemostasis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190910006110/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces Broad Reimbursement Agreement With NHS England for ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor) an Innovative Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis15.7.2025 01:01:00 CEST | Press release
- All eligible people with CF in England can now benefit from this medicine - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it has reached a broad reimbursement agreement with NHS England for Vertex’s cystic fibrosis (CF) medicine ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor). This agreement comes as the National Institute for Health and Care Excellence (NICE) has issued a positive final draft recommendation for this medicine. This next-in-class triple combination treatment is licensed for people living with CF aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “We’re proud that ALYFTREK®, our fifth CF medicine, is available today as another treatment option for all eligible CF patients in England. It represents a significant milestone in our journey to serially innovate and further improve the lives of people living with this disease,” said Lud
SES Receives All Required Regulatory Approvals to Complete Intelsat Acquisition14.7.2025 22:15:00 CEST | Press release
SES received the final regulatory approvals for the SES-Intelsat transaction, including the US Federal Communications Commission. On 30 April 2024, SES and Intelsat announced an agreement for SES to acquire Intelsat for a cash consideration of $3.1 billion (€2.8 billion). The transaction was subject to receipt of relevant regulatory clearances and other relevant requirements which all have now been obtained. As a result, SES plans to close the transaction on or about Thursday, 17 July 2025. Once closing has occurred, a press release will be published to confirm that the transaction has successfully closed. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES SES has a bold vision to deliver amazing experiences everywhere on Earth by distributing the highest quality video content and providing seamless data connectivity services around the world. As a provider of global content and connectivity solutions, SES owns and ope
Loomis Sayles Celebrates 15 Years of Growth Equity Strategies Team Under Leadership of Aziz V. Hamzaogullari14.7.2025 22:05:00 CEST | Press release
Loomis, Sayles & Company: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714614048/en/ 90.7 160 1 BILLION IN ASSETS UNDER MANAGEMENT COMBINED YEARS OF INVESTMENT EXPERIENCE INVESTMENT PHILOSOPHY GES Team As of 5/31/2025 GES Team As of 5/31/2025 Supported by a seven-step research framework Loomis, Sayles & Company proudly celebrates the 15-year anniversary of a differentiated approach to growth equity investing under the leadership of Aziz V. Hamzaogullari, CFA, the founder, chief investment officer and portfolio manager of the Loomis Sayles Growth Equity Strategies (GES) Team. Aziz is also an executive vice president and a member of the firm’s Board of Directors. GES is a cohesive team with nearly 19 years of alpha generation and a long-term, private equity approach to investing. Under Aziz Hamzaogullari’s leadership since 2010, assets under management for GES have grown from $1.9 billion to nearly $91 billion as of 31 Ma
Cessna Skyhawk Soars With Enhanced Efficiency: Solid-State Dual Electronic Ignition System Introduced to the Industry-leading Piston14.7.2025 18:00:00 CEST | Press release
The industry-leading training aircraft, the Cessna Skyhawk, now features a dual electronic ignition system (dual EIS), enhancing maintenance, efficiency and overall operation of the single-engine, high-wing piston. The dual Lycoming electronic ignition system is now standard on all new Cessna Skyhawk aircraft. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250714759359/en/ Cessna Skyhawk soars with enhanced efficiency: solid-state dual electronic ignition system introduced to the industry-leading piston (Photo Credit: Textron Aviation) The Cessna Skyhawk is designed and produced by Textron Aviation Inc., a Textron Inc. (NYSE: TXT) company. The dual EIS replaces the previous dual magneto ignition system on the Skyhawk, incorporating advanced electronic components and reducing the number of internal moving parts to optimize operation. This solid-state electronic technology improves maintenance intervals, fuel efficiency and en
The 2025 Empire State Building Run-Up Returns Oct. 814.7.2025 17:48:00 CEST | Press release
Presented by NYU Langone Health and Powered by the Challenged Athletes FoundationLottery Opens July 14 The Empire State Building (ESB) announced today general lottery registration for the annual Empire State Building Run-Up (ESBRU) on Oct. 8, 2025, at 8 p.m. ESB also announced the ESBRU will be presented by NYU Langone Health and powered by the Challenged Athlete’s Foundation. General lottery registration will be open from July 14 through July 28, 2025. In the 47th annual Run-Up, 225 runners will race up the iconic building’s 1,576 stairs to the world-famous Observatory. This year’s heats will include elite men and women, media, celebrities, New York City real estate brokers, building tenants, CAF athletes, members of the NYPD and FDNY, and the public, among others. On July 30, registered runners will be notified of their race status with participation costs of $175 per runner to be charged only upon acceptance from the lottery. “We are delighted to welcome NYU Langone Health as our ne
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom